Skip to main content
Clinical Trials/CTRI/2024/07/069845
CTRI/2024/07/069845
Not yet recruiting
Phase 2/3

Management of Chronic rhinosinusitis in adults with individualized homoeopathic medicines in different scales- An open label randomized triple arm pragmatic trial

The Calcutta Homoeopathic Medical College and Hospital1 site in 1 country111 target enrollmentStarted: July 10, 2024Last updated:

Overview

Phase
Phase 2/3
Status
Not yet recruiting
Sponsor
The Calcutta Homoeopathic Medical College and Hospital
Enrollment
111
Locations
1
Primary Endpoint
Sino Nasal Outcome Test

Overview

Brief Summary

Chronic rhinosinusitis (CRS) is one of the most common chronic and debilitating conditions affecting 10-15% of the world population. An estimated 134 million Indians suffer from CRS. It has been shown to impair quality of life (QoL) and increase the risk of depression, anxiety, mood and sleep disorders and has significant morbidity and healthcare expenditure. Current management techniques mainly target to reduce inflammation with a variable results and endoscopic sinus surgery (ESS). Though homeopathy is one of the popular choice of CRS patients but effects of classical or individualized form of homeopathy (IH) remained unexplored. In this open label randomized triple arm pragmatic trial at The Calcutta Homoeopathic Medical College and Hospital, 111 patients suffering from CRS will be randomized to receive individualized homoeopathic medicines in centesimal scale(n=37), individualized homoeopathic medicines in decimal scale (n=37),  individualized homoeopathic medicines in fifty millesimalscale (n=37) . We aim to address the feasibility issues of conducting a definitive efficacy trial of individualized homeopathy (IH) in treatment of CRS and to investigate whether there are any differences in outcomes between these three groups over 3 months of intervention. Sino-nasal Outcome Test-22 (SNOT-22) and EQ-5D-5L will be used as the primary and secondary outcome measures respectively. Feasibility issues will be checked and comparative analysis will be carried out to examine group differences, if any.

Study Design

Study Type
Interventional
Allocation
Randomized
Masking
None

Eligibility Criteria

Ages
18.00 Year(s) to 65.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • 1.Patients of both sexes2.Patients of age between 18 to 65 years 3.Patient having chronic rhinosinusitis (CRS) [ICD-11 CA0A.Y] since 12 weeks or more, fulfilling the diagnostic criteria of AAO-HNS50 4.Case presenting with complaints like running nose, headache etc of chronic rhinosinusitis by using SINONASAL OUTCOME TEST (SNOT22)5.Patients undergoing X Ray paranasal sinus which show finding of chronic rhinosinusitis 6.Patients who have not taken any treatment since last 2 weeks for CRS 7.Patients who are literate, can read bengali, hindi, english, capable of filling the questionnaire 8.Providing written informed consent voluntarily.

Exclusion Criteria

  • 1.Cases suffering from uncontrolled systemic illness or life-threatening infections2.Cases suffering from complications of CRS 3.Cases insisting for or in need of surgical interventions, major ENT surgery within last 6 months4.Patients with previous history of nose surgery5.Patients having DNS, cleft lip, otitis media6.Patients who are undergoing treatment with antibiotics, glucocorticoids or antihistamines during 2 weeks prior to enrolment in the study 7.Cases already undergoing homeopathic treatment for any chronic disease since last 6 months8.Substance abuse and/or dependence9.Pregnant, puerperial or lactating women10.Patients with psychiatric diseases11.Self-reported immune-compromised states 12.Vulnerable population – Unconscious, non-ambulatory, too ill for consultation, differently abled, terminally ill or critically ill patients, mentally disabled people13.Simultaneous participation in any other clinical trial.

Outcomes

Primary Outcomes

Sino Nasal Outcome Test

Time Frame: At baseline, and every month, up to 3 months

(SNOT22)

Time Frame: At baseline, and every month, up to 3 months

Secondary Outcomes

  • EQ-5D-5L questionnaire(At baseline, and every month, up to 3 months)

Investigators

Sponsor
The Calcutta Homoeopathic Medical College and Hospital
Sponsor Class
Government medical college
Responsible Party
Principal Investigator
Principal Investigator

Deepak Kumar

The Calcutta Homoeopathic Medical College and Hospital

Study Sites (1)

Loading locations...

Similar Trials